Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 23 March 2026Incoming appointee
6 itemsScheduled Appointment DateEffective 25 June 2026 (formally scheduled to be decided at the Annual General Meeting of Shareholders scheduled for 25 June 2026 and at the Board of Directors meeting to be held after the meeting concludes)
Okamoto Yasuhiro (岡本康寛)
Previous positionDirector, Executive Officer
New positionSenior Managing Director; Executive Officer
Ogama Shinji (大釜信治)
Previous positionExecutive officers
New positionDirector, Executive Officer
Machida Megumi (町田芽久美)
Previous positionNot disclosed
New positionDirector (outside director)
Hattori Hiroyuki (服部浩之)
Previous positionDirector, Executive Officer
New positionFull-time Audit & Supervisory Board Member
Yamamoto Tsutomu (山本務)
Previous positionNot disclosed
New positionExecutive officers
Kajimoto Hiromasa (梶本浩正)
Previous positionNot disclosed
New positionExecutive officers
Departing officer
3 itemsDate of departureEffective 25 June 2026 (Matsuda Mitsunori (松田充功), Takamatsu Teruya (高松輝也)) / effective 1 May 2026 (Tabata Keiichi (田畑啓一))
Matsuda Mitsunori (松田充功)Stepping down
Former PositionOutside Directors
New positionNot disclosed
Takamatsu Teruya (高松輝也)Stepping down
Former PositionFull-time Audit & Supervisory Board Member
New positionNot disclosed
Tabata Keiichi (田畑啓一)Next role stated
Former PositionExecutive officers
New position— (scheduled to be seconded to 株式会社片山製薬所)
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Will not remain on the Board of Directors or Audit & Supervisory Board (Tabata Keiichi (田畑啓一) is scheduled to be seconded to 株式会社片山製薬所)
Directors after the change8Number
Filing as an independent officerThe above 4 outside directors and 2 outside Audit & Supervisory Board Members are scheduled to be designated as independent officers and reported to the Tokyo Stock Exchange.
Shareholders’ meeting approvalYes. Formal decisions are scheduled to be made at the Annual General Meeting of Shareholders scheduled for 25 June 2026 and at the Board of Directors meeting to be held after the meeting concludes.
Independent officers are outside officers registered with the exchange as having no conflict of interest with general shareholders.
| Item | Details |
|---|---|
| Resolution date | 23 March 2026 |
| Scheduled Appointment Date | Effective 25 June 2026 (formally scheduled to be decided at the Annual General Meeting of Shareholders scheduled for 25 June 2026 and at the Board of Directors meeting to be held after the meeting concludes) |
| Date of departure | Effective 25 June 2026 (Matsuda Mitsunori (松田充功), Takamatsu Teruya (高松輝也)) / effective 1 May 2026 (Tabata Keiichi (田畑啓一)) |
| Name of appointee | Okamoto Yasuhiro (岡本康寛), Ogama Shinji (大釜信治), Machida Megumi (町田芽久美), Hattori Hiroyuki (服部浩之), Yamamoto Tsutomu (山本務), Kajimoto Hiromasa (梶本浩正) |
| Appointee's new position | Senior Managing Director; Executive Officer, Director, Executive Officer, Director (outside director), Full-time Audit & Supervisory Board Member, Executive officers, Executive officers |
| Appointee's previous position | Director, Executive Officer, Executive officers, Not disclosed, Director, Executive Officer, Not disclosed, Not disclosed |
| Name of departing officer | Matsuda Mitsunori (松田充功), Takamatsu Teruya (高松輝也), Tabata Keiichi (田畑啓一) |
| Former position of departing officer | Outside Directors, Full-time Audit & Supervisory Board Member, Executive officers |
| New position of departing officer | Not disclosed, Not disclosed, — (scheduled to be seconded to 株式会社片山製薬所) |
| Whether the incumbent will remain in office | Will not remain on the Board of Directors or Audit & Supervisory Board (Tabata Keiichi (田畑啓一) is scheduled to be seconded to 株式会社片山製薬所) |
| Number of directors after the change | 8 Directors, including 4 Outside Directors |
| Filing as an independent officer | The above 4 outside directors and 2 outside Audit & Supervisory Board Members are scheduled to be designated as independent officers and reported to the Tokyo Stock Exchange. |
| Subject to Approval by the General Meeting of Shareholders | Yes. Formal decisions are scheduled to be made at the Annual General Meeting of Shareholders scheduled for 25 June 2026 and at the Board of Directors meeting to be held after the meeting concludes. |
Items this document does not state (8)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.